We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ABBOTT DEFENDS PRICE HIKE FOR NORVIR AS TRUE MARKET VALUE
ABBOTT DEFENDS PRICE HIKE FOR NORVIR AS TRUE MARKET VALUE
May 28, 2004
Under legal fire from a wide-ranging assortment of litigants, Abbott Laboratories defended its 400 percent price hike on the AIDS drug Norvir, saying the increase reflects the true market value of the product, which remains the lowest-priced drug at its dose in the protease inhibitor class.